Sunday September 22, 2019

Breast Cancer Drugs may Force Some Cancer Cells into ‘Sleeper Mode’

The team studied human breast cancer cells in the laboratory and examined the effects of a group of breast cancer drugs called hormone treatments

0
//
Breast Cancer, Drugs, Cells
The research could open avenues for finding ways of keeping the cancer cells dormant for longer, or even potentially finding a way of awakening the cells so they can then be killed by the treatment. Pixabay

Breast cancer drugs may force some cancer cells into ‘sleeper mode’, allowing them to potentially come back to life years after initial treatment.

The research could open avenues for finding ways of keeping the cancer cells dormant for longer, or even potentially finding a way of awakening the cells so they can then be killed by the treatment.

The team studied human breast cancer cells in the laboratory and examined the effects of a group of breast cancer drugs called hormone treatments.

“For a long time scientists have debated whether hormone therapies – which are a very effective treatment and save millions of lives – work by killing breast cancer cells or whether the drugs flip them into a dormant ‘sleeper’ state,” said Luca Magnani, lead author of the study from Imperial College London.

Breast Cancer, Drugs, Cells
Breast cancer drugs may force some cancer cells into ‘sleeper mode’, allowing them to potentially come back to life years after initial treatment. Pixabay

“This is an important question as hormone treatments are used on the majority of breast cancers. Our findings suggest the drugs may actually kill some cells and switch others into this sleeper state,” Magnani added.

“If we can unlock the secrets of these dormant cells, we may be able to find a way of preventing cancer coming back, either by holding the cells in permanent sleep mode, or be waking them up and killing them,” Magnani said.

In the study, published in the journal Nature Communications, the team studied around 50,000 human breast cancer single cells in the lab, and found that treating them with hormone treatment exposed a small proportion of them as being in a dormant state.

The ‘sleeper cells’ may also provide clues as to why some breast cancer cells become resistant to treatment, causing a patient’s drugs to stop working, and their cancer to return, the researchers said.

Also Read- Killer Gorge in Hell’s Gate National Park Closed after 7 killed

Hormone therapies are used to treat a type of breast cancer called oestrogen-receptor positive. These make up over 70 per cent of all breast cancers, and are fuelled by the hormone oestrogen.

These cancers are usually treated with surgery to remove the tumour, followed by a course of targeted hormone therapy – usually either aromatase inhibitors or tamoxifen, which target oestrogen receptors.

However, around 30 per cent of breast cancer patients taking hormone therapies see their cancer eventually return – sometimes as long as 20 years after treatment.

This returning cancer is usually metastatic, meaning it has spread around the body, and the tumours are often now resistant to medication. (IANS)

Next Story

Donepezil, A Drug Used For Alzheimer Disease, Doubles Hospitalisation Risk

Researchers have found that a drug, donepezil commonly used to manage symptoms of Alzheimer disease and other forms of dementia, is associated with a two-fold higher risk of hospitalisation

0
Drugs, Alzheimer, Dementia, Hospitalisation, Risk
Dementia is a growing problem, with almost 10 million newly diagnosed cases every year around the world. Pixabay

Researchers have found that a drug, donepezil commonly used to manage symptoms of Alzheimer disease and other forms of dementia, is associated with a two-fold higher risk of hospitalisation.

According to the study published in the journal Canadian Medical Association Journal (CMAJ), using donepezil increases the risk of hospital admission for rhabdomyolysis, a painful condition of muscle breakdown, compared with several other cholinesterase inhibitors.

Dementia is a growing problem, with almost 10 million newly diagnosed cases every year around the world, said the researchers.

Drugs, Alzheimer, Dementia, Hospitalisation, Risk
Dr. William Burke goes over a PET brain scan, Aug. 14, 2018 at Banner Alzheimers Institute in Phoenix, Arizona. VOA

“The findings of this population-based cohort study support regulatory agency warnings about the risk of donepezil-induced rhabdomyolysis,” said study researcher Jamie Fleet from McMaster University in Canada.

The study, led by researchers at Western University, looked at ICES data from 2002 to 2017 on 2,20,353 patients aged 66 years or older in Ontario, Canada, with a new prescription for donepezil, rivastigmine or galantamine, three cholinesterase inhibitors used to manage dementia and Alzheimer disease.

ALSO READ: Gas-Capturing Capsules To Measure What Gases You Have

The researchers found that donepezil was associated with a two-fold higher risk of hospitalisation for rhabdomyolysis, a serious condition that can result in kidney disease.

According to the findings, the relative risk was small but statistically significant. (IANS)